Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report

References

• Anderson M, Campbell F, Choiniere M, El-Gabalawy H, Hudspith M, Laliberte J, Swidrovich J, Wilhelm L. Canadian pain task force report: an action plan for pain in Canada. Ottawa (ON): Health Canada; June 2019.
   Google Scholar
• Dassieu L, Kaboré JL, Choinière M, Arruda N, Roy É. Chronic pain management among people who use drugs: a health policy challenge in the context of the opioid crisis. Int. J. Drug Policy. 2019;71:150–56. doi:10.1016/j.drugpo.2019.03.023.
   PubMed Web of Science ®Google Scholar
• Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia—when is enough too much? A review of opioid-induced tolerance and hyperalgesia. The Lancet. 2019;393(10180):1558–68. doi:10.1016/S0140-6736(19)30430-1.
   PubMed Web of Science ®Google Scholar
• Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017;189(18):E659–E666. doi:10.1503/cmaj.170363.
   PubMed Web of Science ®Google Scholar
• Canadian Headache Society. Choosing wisely Canada - headache. Published 2020. Accessed March 23, 2022. https://choosingwiselycanada.org/recommendation/headache/
   Google Scholar
• Fisher MA, Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology. 1997;48(5):1156–60. doi:10.1212/wnl.48.5.1156.
   PubMed Web of Science ®Google Scholar
• Commiskey S, Fan LW, Ho IK, Rockhold RW. Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005;98(2):109–16. doi:10.1254/jphs.crj05001x.
   Web of Science ®Google Scholar
• Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker W. Canadian headache society guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013;40(5 Suppl 3):S1–S80.
   PubMed Web of Science ®Google Scholar
• Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, et al. Managing opioid use disorder in primary care. Can Family Physician. 2019;65(5):321. http://www.cfp.ca/content/65/5/321.abstract.
   PubMed Web of Science ®Google Scholar
• Chen KY, Chen L, Mao J. Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014;120(5):1262–74. doi:10.1097/ALN.0000000000000170.
   PubMed Web of Science ®Google Scholar
• Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679–84.
   PubMed Web of Science ®Google Scholar
• Kumar R, Viswanath O, Saadabadi AB. In: statPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 August 6. 2022 Jan. PMID: 29083570.
   Google Scholar
• Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Medicine. 2014;15(12):2087–94. doi:10.1111/pme.12520.
   PubMed Web of Science ®Google Scholar
• Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J JR. Conversion of chronic pain patients from full opioid agonists to sublingual buprenorphine. Pain Physician. 2012 Jul;15(3 Suppl):E259–66.
   Web of Science ®Google Scholar
• Brar R, Fairbairn N, Sutherland C, Nolan S. Use of a novel prescribing approach for the treatment of opioid use disorder: buprenorphine/naloxone micro-dosing - a case series. Drug Alcohol Rev. 2020;39(5):588–94. doi:10.1111/dar.13113.
   PubMed Web of Science ®Google Scholar
• Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dursteler KM, Vogel M. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105. doi:10.2147/SAR.S109919.
   PubMed Web of Science ®Google Scholar
• Sandhu R, Zivanovic R, Klaire S, Nikoo M, Rozylo J, Azar P. Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: a case report. Canadian Journal of Pain. 2019;3(1):79–84. doi:10.1080/24740527.2019.1599279.
   PubMed Web of Science ®Google Scholar
• Buprenorphine/naloxone. Monograph. Published August 2017. Accessed October 6, 2021. https://pdf.hres.ca/dpd_pm/00041002.PDF
   Google Scholar
• Randhawa PA, Brar R, Nolan S. Buprenorphine–naloxone “microdosing”: an alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market. Can. Med. Assoc. J . 2020;192(3):E73. doi:10.1503/cmaj.74018.
   PubMed Web of Science ®Google Scholar
• Halpape K, Jorgenson D, Ahmed A, Kizlyk K, Landry E, Marwah M, Raiche T, Wiebe A. Pharmacist-led strategy to address the opioid crisis: the medication assessment centre interprofessional opioid pain service (MAC iOPS). Can. Pharm. J./Revue Des Pharmaciens du Canada. Published online September 21, 2021, 17151635211045950. doi:10.1177/17151635211045950.
   Google Scholar
• Knisely JS, Wunsch MJ, Cropsey KL, Campbell ED. Prescription opioid misuse index: a brief questionnaire to assess misuse. J Subst Abuse Treat. 2008;35(4):380–86. doi:10.1016/j.jsat.2008.02.001.
   PubMed Web of Science ®Google Scholar
• Mayer TG, Neblett R, Cohen H, Howard HJ, Choi YH, Williams MJ, Perez Y, Gatchel RJ. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012;12(4):276–85. doi:10.1111/j.1533-2500.2011.00493.x.
   PubMed Web of Science ®Google Scholar
• Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133–37. doi:10.1016/j.jpain.2003.12.005.
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1–2):29–36. doi:10.1016/j.pain.2004.12.010.
   PubMed Web of Science ®Google Scholar
• Sullivan MJ, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess. 1995;7:524–32.
   Web of Science ®Google Scholar
• VonVoigtlander PF, Lewis RA. A withdrawal hyperalgesia test for physical dependence: evaluation of mu and mixed-partial opioid agonists. J Pharmacol Methods. 1983;10(4):277–82. doi:10.1016/0160-5402(83)90022-0.
   Google Scholar
• Gillis JC, Benfield P, Goa KL. Transnasal Butorphanol. Drugs. 1995;50(1):157–75. doi:10.2165/00003495-199550010-00010.
   Google Scholar
• AA Pharma INC. Butorphanol nasal spray. Vaughan (Ont), 2018. Accessed April 13, 2022. https://pdf.hres.ca/dpd_pm/00045595.PDF
   Google Scholar
• Broglio K, Portenoy K. Approximate dose conversion for commonly used opioids. UpToDate 2021, Accessed April 13, 2022. https://www.uptodate.com/contents/image?imageKey=PALC%2F111216&topicKey=PALC%2F86302&source=see_link
   Google Scholar
• Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–70. doi:10.2147/JPR.S85951.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 1991;41(3):326–44. doi:10.2165/00003495-199141030-00002.
   PubMed Web of Science ®Google Scholar
• Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211–28. doi:10.1007/s40265-018-0953-z.
   PubMed Web of Science ®Google Scholar
• Patel P, Dunham K, Lee K. Buprenorphine/naloxone microdosing: the bernese method a brief summary for primary care clinicians. Can. Mental Health Assoc. 2019. Accessed September 3, 2021. https://www.metaphi.ca/wp-content/uploads/Guide_Microdosing.pdf
   Google Scholar
• Marwah R, Coons C, Myers J, Dumont Z. Buprenorphine-naloxone microdosing: tool for opioid agonist therapy induction. Can. Family Physician Medecin de Famille Canadien. 2020;66(12):891–94. doi:10.46747/cfp.6612891.
   PubMed Web of Science ®Google Scholar